Mechanisms of Action of the KCa2-Negative Modulator AP30663, a Novel Compound in Development for Treatment of Atrial Fibrillation in Man.

Bentzen BH, Bomholtz SH, Simó-Vicens R, Folkersen L, Abildgaard L, Speerschneider T, Muthukumarasamy KM, Edvardsson N, Sørensen US, Grunnet M, Diness JG

Open source

DOI: 10.3389/fphar.2020.00610
Published: 2020
Container: Frontiers in pharmacology
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.3389/fphar.2020.00610,
  title = {Mechanisms of Action of the KCa2-Negative Modulator AP30663, a Novel Compound in Development for Treatment of Atrial Fibrillation in Man.},
  author = {Bentzen BH and Bomholtz SH and Simó-Vicens R and Folkersen L and Abildgaard L and Speerschneider T and Muthukumarasamy KM and Edvardsson N and Sørensen US and Grunnet M and Diness JG},
  year = {2020},
  journal = {Frontiers in pharmacology},
  doi = {10.3389/fphar.2020.00610},
  url = {https://doi.org/10.3389/fphar.2020.00610}
}

RIS

TY  - JOUR
TI  - Mechanisms of Action of the KCa2-Negative Modulator AP30663, a Novel Compound in Development for Treatment of Atrial Fibrillation in Man.
AU  - Bentzen BH
AU  - Bomholtz SH
AU  - Simó-Vicens R
AU  - Folkersen L
AU  - Abildgaard L
AU  - Speerschneider T
AU  - Muthukumarasamy KM
AU  - Edvardsson N
AU  - Sørensen US
AU  - Grunnet M
AU  - Diness JG
PY  - 2020
JO  - Frontiers in pharmacology
DO  - 10.3389/fphar.2020.00610
UR  - https://doi.org/10.3389/fphar.2020.00610
ER  -

APA

BH, B., SH, B., R, S., L, F., L, A., T, S., KM, M., N, E., US, S., M, G., & JG, D. (2020). Mechanisms of Action of the KCa2-Negative Modulator AP30663, a Novel Compound in Development for Treatment of Atrial Fibrillation in Man.. Frontiers in pharmacology. https://doi.org/10.3389/fphar.2020.00610

Source records

pubmed · retrieved 2026-09-25T22:38:18.697Z